Sign up
Pharma Capital

Amryt Pharma expands route to market for key product

It has inked an exclusive distribution deal with GryNumber Health covering Central and Eastern Europe
men shaking hands
Deal done - the company's new partner has a well established network in the region

Amryt Pharma PLC (LON:AMYT) said it has expanded its route to market its key product Lojuxta.

It has inked an exclusive distribution deal with GryNumber Health covering Central and Eastern Europe, building on similar deals in Saudi Arabia and Switzerland.

READ: Amryt Pharma signs exclusive distributor agreement in Switzerland

"GryNumber Health has a well-established presence in, and significant experience of, the healthcare markets in Central and Eastern Europe and therefore is an ideal partner for us in the region,” said Dr Joe Wiley, Amryt chief executive.

“We are delighted to have signed this exclusive distribution agreement as we look to provide access to Lojuxta to patients suffering from HoFH across our licensed territories."

READ: Amryt Pharma inks exclusive Saudi Arabian distribution agreement for its Lojuxta and AP101 drugs

The company acquired the rights to sell Lojuxta in certain territories just over a year ago. The drug is used to treat a rare and potentially life-threatening genetic disorder called homozygous familial hypercholesterolemia, which is characterised by high LDL cholesterol levels.

View full AMYT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.